Research Article

Integrated Analysis of miR-7-5p-Related ceRNA Network Reveals Potential Biomarkers for the Clinical Outcome of Gastric Cancer

Meng-Yang Shi, Yan-fei Mu, and Neng Shen

Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Shapingba District, Chongqing, China

Correspondence should be addressed to Neng Shen; shenneng9527@cqu.edu.cn

Received 7 January 2022; Revised 22 January 2022; Accepted 27 January 2022; Published 14 February 2022

Gastric cancer (GC) is the second leading cause of tumor-associated death and the fourth most commonly seen tumor across the world. Abnormal ncRNAs have been verified to be involved in potential metastasis via modulating epithelial-to-mesenchymal transition progression and are vital for the progression of cancers. Tumor-infiltrating immune cells (TICs) are a vital indicator of whether cancer patients will benefit from immunotherapy. Nonetheless, the association between ceRNAs and immune cells remained largely unclear. We used the ceRNA network combined with TICs for the prediction of the clinical outcome of GC patients based on TCGA datasets. The percentage of immunocytes in GC was speculated by the use of CIBERSORT. Via Lasso and multivariate assays, prognostic models were established applying survival-related genes and immune cells. Nomograms were developed, and the accuracy of the nomograms was determined using calibration curves. The association between ceRNAs and TICs was validated by the use of integration analysis. In this study, there were 2219 mRNAs (1308 increased and 911 decreased), 171 lncRNAs (51 decreased and 120 increased), and 123 miRNAs (55 decreased and 68 increased) differentially expressed between tumor groups and nontumor groups. Five lncRNAs, six miRNAs, and 64 mRNAs were used for ceRNA network construction. Eight genes including LOX, SPARC, MASTL, PI15, BMPR1B, ANKRD13B, PVT1, and miR-7-5p were applied for the development of the prognostic model. Survival assays suggested that tumor cases with high risk exhibited a shorter overall survival. In addition, we included T-cell CD4 memory activated, monocytes, and neutrophils for the development of a prognosis model. Eventually, our team demonstrated the possible associations between the ceRNA prognosis model and prognostic model based on immune cells. To sum up, the ceRNA network could be used for gene regulation and predict clinical outcomes of GC patients.

1. Introduction

Gastric cancer (GC) is one of the most commonly seen malignancies, which has approximately one million new cases diagnosed annually [1]. GC has an especially high prevalence in Asia [2]. Even with recent improvements in surgery and chemotherapy, GC remains with a very high morbidity and mortality because most patients are diagnosed at an advanced stage and accompanied by malignant proliferation and extensive lymphatic metastasis [3, 4]. Hence, it is imperative to further understand the biomechanism beneath GC and identify new diagnosis/prognosis markers in this regard.

Long noncoding RNAs (lncRNAs), without protein-coding functions, have aroused more and more academic interest in recent years [5]. These RNAs are vital for diverse BP, especially various cancers [6]. The ceRNA assumption hypothesized that apart from the traditional functions, miRNAs targeting RNAs, a reversed logic exists [7, 8]. Growing evidence has demonstrated that lncRNAs, miRNAs, and mRNAs exhibited important regulatory functions in the development and progression of various tumors [9, 10]. Importantly, many ncRNAs have been demonstrated to regulate tumor metastasis via the EMT pathway. Based on the theory of ceRNA, lncRNA and mRNA may have the identical miRNA response elements.
Thus, when miRNAs bind to miRNA response elements on lncRNAs, the expressions of mRNAs may not be suppressed, which could promote tumor progression [11, 12]. More and more researchers have suggested that the exploration of RNA interactions is very important for the improvements of the treatments of various tumors [13, 14]. Based on the above findings, specific lncRNA-miRNA-mRNA ceRNA networks have been developed for many kinds of cancers [15, 16]. However, at the genome-wide scale, the studies involved in comprehensive assays between miRNAs and lncRNAs were rarely reported. So, this research intended to construct a risk-assessment model for the prediction of the clinical outcome of GC patients.

2. Materials and Methods

2.1. Data Collection and Processing. The stomach adenocarcinoma (STAD) transcriptomic data of HTseq-count were acquired on July 4, 2021, from TCGA database, involving mRNA, lncRNA, and miRNA expression patterns of 375 STAD tissues and 32 noncancerous tissues. Corresponding clinical information including sex, age, survival time, and survival status was downloaded from TCGA on the same day. The abundance data of tumor immune infiltration were obtained from the CIBERSORT database, containing 22 types of immunocytes. Genetic expression information of STAD sufferers and tumor immune infiltration abundance data were combined for obtaining the immune cell infiltration abundance of STAD patients.

2.2. Differentially Expressed RNAs’ Screening and ceRNA Network Construction. After pooling unmatched probes and calculating the average value when the same RNA was detected multiply, 35668 RNAs including 19064 mRNAs, 14086 lncRNAs, and 2518 miRNAs were used for further analysis. Then, 35668 RNAs, including 19064 mRNAs, 14086 lncRNAs, and 2518 miRNAs, were used for further analysis. “Deseq2” package was used to screen differentially expressed RNAs [17]. log2 FCs > 1 and modified \( p < 0.05 \) had significance on statistics. The visualization of these RNA differential expressions was realized by “heatmap” package and used for constructing the ceRNA network. The ceRNA network, showing the interactions between lncRNA-miRNA and miRNA-mRNA, was established via GDC RNA Kits and visualized by Cytoscape software 3.8.0 [18].

2.3. Prognostic Model of Survival-Associated Genes in the ceRNA Network. Univariate assays were applied to screen survival-associated genes within the ceRNA network, aiming to prevent the model from overfitting. Thereafter, the Lasso regression analysis was completed. A prognostic model, via multivariate Cox regression analyses, was constructed to forecast the survival rate of STAD patients. According to the RS computed by the prognosis model, sufferers were separated into the risk_high group and risk_low group to explore the survival difference. The accuracy of the model was tested by ROC and the correction curves in the “survival” R package.

2.4. Estimation of Immune Cell Infiltration. The 22 types of immunocyte classes in STAD were evaluated by the CIBERSORT algorithm. The specimens with CIBERSORT results of \( p < 0.05 \) were utilized for analyses. The relative abundance of immunocytes in STAD sufferers was calculated. The correlations of immune cells were estimated. To compare the diverse ICI in tumor and normal samples, the Wilcoxon rank-sum test was used.

2.5. Survival Analyses and Prognostic Model of Prognosis-Associated Tumor Immune Cells. K-M analyses were performed for every kind of immune cells to find survival-associated immune cells. Immunocytes with \( p < 0.05 \) were used for further analyses. Prognosis-associated infiltration immunocyte classes were subjected to selection via univariable Cox regression analyses. Lasso regression analyses were utilized to ensure the most proper immune cell types for model construction. A model was established via the regressive coefficients of multivariable Cox regression analyses. The risk scores separated sufferers into the risk_high group and risk_low group to explore the survival difference. The ROC and the correction curves were used to identify the nomogram’s accurateness.

3. Statistical Analysis

All analyses were conducted by Perl 5.30.1 (Holland, MI, USA) and R 3.6.2 (R Core Team, Boston, USA).

4. Results

4.1. Identification of Differentially Expressed Genes and Construction of the ceRNA Network. There were 2219 mRNAs (1308 downregulated and 911 upregulated) (Figures 1(a) and 1(b)), 171 lncRNAs (51 downregulated and 120 upregulated) (Figures 1(c) and 1(d)), and 123 miRNAs (55 downregulated and 68 upregulated) differentially expressed between experiment and control groups (Figures 1(e) and 1(f)). Then, the relationships between miRNA-mRNA and lncRNA-miRNA were calculated, and RNAs without regulation relationships were excluded. Finally, 5 lncRNAs, 6 miRNAs, and 64 mRNAs were used for ceRNA network construction. Eventually, we identified 74 edges and 75 nodal points within the network (Figure 2).

4.2. Identification of Prognosis-Associated Genes within the ceRNA Network and Establishment of a Prognosis Model. After combining the survival data (status and time) and the gene expression data, we performed univariable Cox regression analyses and found 19 genes related to survival. To avoid overfitting, we performed Lasso regression analysis (Figures 3(a) and 3(b)). Eight genes (LOX, SPARC, MASTL, PI15, BMP11B, ANKRD13B, PVT1, and hsa-miR-7-5p) were involved in a Cox proportion risk model used to assess prognosis results (Figure 3(c)). The sufferers were separated into the risk_high group and risk_low group on the foundation of the model. The survival analyses revealed that the risk_high sufferers displayed poorer OS (\( p < 0.001 \)) (Figure 3(d)). The
Figure 1: Thermographs and volcano plots of RNA differential expression. (a, b) mRNAs, (c, d) lncRNAs, and (e, f) miRNAs. Red dots represented RNAs with an increased expression, and green dots represented RNAs with a decreased expression.
ROC curve revealed that the AUC of 1-year survival registered 0.669, AUC of 3-year survival registered 0.665, and AUC of 5-year survival registered 0.691, suggesting an acceptable accuracy of this model (Figure 3(e)). A nomograph was drawn to forecast the 1-year, 2-year, and 3-year OS potential of STAD sufferers on the foundation of this model (Figure 4(a)). The calibration curve also showed an acceptable accuracy of this nomogram (Figure 4(b)).

4.3. Tumor Immune Infiltration. The relative percentage of cancer-infiltrating immunocytes in STAD patients was evaluated via CIBERSORT arithmetic (Figure 5(a)). The correlations of immune cells were calculated (Figure 5(b)). Compared with normal tissues, B-cell naïve, T-cell CD4 memory stimulated, Tfh, macrophages M0, macrophages M1, and macrophages M2 were highly expressed in STAD tissues significantly. Meanwhile, B-cell memory, plasmic cells, T-cell CD8, monocytes, and mast cells resting were lower expressed in STAD tissues significantly (Figure 5(c)).

4.4. Determination of Prognosis-Associated Immune Infiltration Cells and Construction of a Prognosis Model. Through K-M assays, our group observed that patients with higher proportions of T-cell CD4 memory stimulated, Tfh, and Tregs had better survival (Figures 6(a)–6(c)). Lasso regression and univariable Cox regressive analysis were completed to determine prognosis-associated infiltrating immune cells. The results suggested that T-cell CD4 memory stimulated, monocytes, and neutrophils had better abilities in forecasting prognoses (Figures 6(d)–6(f)). Afterwards, a prognostic model was developed by the use of multivariate assays. On the foundation of the model, sufferers were separated into risk high and risk low groups. Compared with the low-risk group, risk high sufferers displayed shorter survival ($p = 0.009$) (Figure 7(a)). The model accurateness was identified by the ROC curves (Figure 7(b)). On the foundation of the model, we constructed a nomograph to forecast the 1-year survival, 2-year survival, and 3-year survival of STAD sufferers (Figure 7(c)). Our team found satisfactory accurateness of such a nomograph was realized through the calibration curve (Figure 7(d)).
Figure 3: The results of Lasso regression and the model constructed by multivariate assays. (a) Lasso coefficient profiles of the 8 genes related to prognoses from the key members of the ceRNA network. (b) The Lasso regression model for partial likelihood deviance of variables. (c) Multivariate assays of 8 prognosis-associated genes for the development of the prognosis model. (d) Survival assays of patients in the risk_{high} group and risk_{low} group based on the model. (e) ROC curve was employed to verify the model accuracy.
4.5. Association between Genes and Immunocytes for Prognosis. A correlation test was conducted to investigate the relationship between the 8 genes and 3 infiltration immunocytes used for constructing prognostic models (Figure 8(a)). We found that neutrophils were positively associated with PI15, indicating that patients with higher PI15 expression would have more neutrophil infiltration in tumors (Figure 8(b)). For STAD patients, PI15 expression and neutrophil infiltration may be effective prognostic biomarkers.

5. Discussion

GC is still a primary public health concern as the 4th most commonly seen tumor and the 2nd leading cause of tumor mortality across the globe [19]. The latest development in genomic, proteomic, and metabolomic techniques has discovered pivotal molecule events in the course of GC carcinogenesis [20]. The findings give rise to the identification of new GC markers, such as gene and epigenesis variations, mRNA, ncRNA, posttranslation protein modification, and
| T cells CD4 memory activated | T cells CD4 naive | Macrophages M0 | Macrophages M1 | Macrophages M2 | Mast cells activated | Mast cells resting | NK cells activated | NK cells resting | B cells memory | B cells naive | Plasma cells | Neutrophils | Eosinophils | Monocytes | Macrophages M2 | Macrophages M1 | Dendritic cells activated | Dendritic cells resting |
|-----------------------------|------------------|----------------|----------------|----------------|---------------------|-------------------|------------------|-----------------|----------------|-------------|--------------|------------|-------------|----------|----------------|----------------|------------------|----------------------|
| 1                           | 0.02             | 0.21           | 0.29           | 0.37           | 0.01                | 0.1               | 0.04             | 0.08            | 0.19           | 0.04        | 0.04         | 0.12       | 0.04         | 0.12     | 0.01           | 0.01           | 0.2              | 0.11                | 0.14             | 0.12             | 0.2               | 0.13             | 0.22             | 0.04             | 0.04             | 0.12 | 0.04 | 0.12 |
| 0.8                         | 0.6              | 0.4            | 0.2            | 0              | 0.8                 | 0.4               | -0.4             | -0.6            | -0.4           | -0.6        | -0.2         | -0.8        | -0.4        | -0.2      | -0.8        | 0.4             | 0.2              | -0.4            | -0.6             | -0.4            | -0.6             | -0.2            | -0.8            | 0.4             | -0.4            | -0.2 | -0.8 | 0.4 |
| 0.4                         | 0.2              | 0              | 0.03           | 0.01           | 0.02                | 0.01              | 0.04             | 0.06            | 0.04           | 0.06        | 0.05         | 0.02       | 0.04        | 0.05     | 0.02        | 0.04             | 0.06            | 0.04            | 0.06             | 0.04            | 0.06            | 0.05            | 0.02            | 0.04            | 0.05 | 0.02 | 0.04 |
| 0.2                         | 0.1              | 0.03           | 0.01           | 0.01           | 0.02                | 0.01              | 0.04             | 0.06            | 0.04           | 0.06        | 0.05         | 0.02       | 0.04        | 0.05     | 0.02        | 0.04             | 0.06            | 0.04            | 0.06             | 0.04            | 0.06            | 0.05            | 0.02            | 0.04            | 0.05 | 0.02 | 0.04 |
| 0.2                         | 0.1              | 0.03           | 0.01           | 0.01           | 0.02                | 0.01              | 0.04             | 0.06            | 0.04           | 0.06        | 0.05         | 0.02       | 0.04        | 0.05     | 0.02        | 0.04             | 0.06            | 0.04            | 0.06             | 0.04            | 0.06            | 0.05            | 0.02            | 0.04            | 0.05 | 0.02 | 0.04 |
| 0.1                         | 0.03             | 0.01           | 0.01           | 0.01           | 0.02                | 0.01              | 0.04             | 0.06            | 0.04           | 0.06        | 0.05         | 0.02       | 0.04        | 0.05     | 0.02        | 0.04             | 0.06            | 0.04            | 0.06             | 0.04            | 0.06            | 0.05            | 0.02            | 0.04            | 0.05 | 0.02 | 0.04 |
| 0.1                         | 0.03             | 0.01           | 0.01           | 0.01           | 0.02                | 0.01              | 0.04             | 0.06            | 0.04           | 0.06        | 0.05         | 0.02       | 0.04        | 0.05     | 0.02        | 0.04             | 0.06            | 0.04            | 0.06             | 0.04            | 0.06            | 0.05            | 0.02            | 0.04            | 0.05 | 0.02 | 0.04 |
| 0.01                        | 0.01             | 0.01           | 0.01           | 0.01           | 0.02                | 0.01              | 0.04             | 0.06            | 0.04           | 0.06        | 0.05         | 0.02       | 0.04        | 0.05     | 0.02        | 0.04             | 0.06            | 0.04            | 0.06             | 0.04            | 0.06            | 0.05            | 0.02            | 0.04            | 0.05 | 0.02 | 0.04 |

**Figure 5: Continued.**
**Figure 5:** TIIICs in the tumor tissues. (a) The relative percentage of 22 TIIICs in STAD patients. (b) The correlation of 22 types of TIIICs in STAD sufferers. (c) Diversity in the percentage of 22 TIIICs between cancer specimens and nontumor specimens.

**Figure 6:** Continued.
**Figure 6:** Identification of survival-associated infiltration immunocytes and construction of a prognosis model. (a–c) Survival assays of patients with different proportions of T-cell CD4 memory stimulated, Th1, and Tregs via Kaplan–Meier analysis. (d) Lasso coefficient profiles of the 22 TIICs. (e) The Lasso regression model for partial likelihood deviance of variables. (f) Multivariate assays of infiltrating immune cells.

**Figure 7:** Results of the TIIC prognostic model. (a) Survival assays of patients in the risk_high group and risk_low group. (b) ROC curve was employed to identify the model accuracy. (c) Nomogram was employed to forecast sufferers’ survival time. (d) Correction curve of the nomograph.
metabolin [21, 22]. ceRNA modulatory networks have become hotspots in tumor studies. Previously, several studies have reported the potential of a prognostic model based on the ceRNA network in several types of tumors [23, 24]. In this study, we analyzed TCGA datasets and screened dysregulated lncRNA, miRNA, and mRNA. Then, we developed the ceRNA network of differentially expressed RNAs. Based on the above results, we acquired a prognosis model on the foundation of eight genes (LOX, SPARC, MASTL, PI15, BMPR1B, ANKR13B, PVT1, and hsa-miR-7-5p). Survival assays confirmed that riskhigh sufferers exhibited undesirable prognoses. ROC assays further confirmed the prognosis significance of our model in GC sufferers, highlighting the potential of our model used as a novel prognostic system.

Previously, the function of the eight genes has been reported in GC. For instance, the expression of miR-7-5p was reported to be low in GC stem cells, and its overexpression distinctly suppressed the growth and invasion of GC stem cells via increasing Smo and Hes1 [25]. SPARC belongs to the matricellular family of secreted proteins. Previous several studies reported that SPARC expression was distinctly increased in gastric cancer, and its knockdown suppressed the metastasis and EMT progress of GC cells [26]. In addition, PVT1, an overexpressed lncRNA in GC, was demonstrated to promote the proliferation and the development of multidrug resistance [27]. Their findings suggested the above genes acted as tumor promoters or suppressors in GC progression, which explained the reason that patients with high risk showed a shorter overall survival.

Then, to further forecast the prognoses of GC sufferers at diverse years posterior to diagnoses, our team established a novel nomograph on the foundation of genetic expression. The greater the overall scoring of the sufferer, the poorer the prognostic result.

Substantial research studies have recorded an association between the immunity infiltration in some mankind tumor types and prognoses and responses to treatments [28, 29]. Infiltration immunocytes are utilized as markers for the immune therapy reaction in multiple tumors [30]. Nevertheless, the role of each infiltration immunocyte type in tumor progression and the potential causal link remain elusive. Herein, our team established a prognosis model on the foundation of T-cell CD4 memory stimulated, monocytes, and neutrophils. The three immunocytes were related to OS of GC sufferers. In addition, survival assays confirmed that riskhigh GC sufferers showed a shorter OS in contrast to risklow sufferers, which was further confirmed by ROC assays. Finally, our team identified the association between the ceRNA prognosis model and the infiltration immunocyte prognosis model. Neutrophils were associated with PI15 in a positive way, which might reveal that the greater the expressions of such a gene, the greater the ICI level. Previously, PI15 was discovered to be dysregulated in several types of tumors, and its diagnostic and prognostic value was frequently reported [31–33]. However, the possible regulatory function between PI15 and immunity remained unknown, which needed further study. In addition, the potential of PI15 used as a biomarker for the depth of neutrophil infiltration needed to be further demonstrated in other experiments.

6. Conclusion

Overall, the two models can be used as reliable prognostic biomarkers for GC and can provide guidance for personalized therapy. More studies are needed for the demonstration of our findings using clinical experiments and in vitro and in vivo assays.
Abbreviations

GC: Gastric cancer  
ICl: Immune cell infiltration  
IncRNAs: Long noncoding RNAs  
STAD: Stomach adenocarcinoma  
Tregs: T cells  
FC: Fold changes  
ROC: Receiver operating characteristic curves  
ceRNA: Competitive endogenous RNA  
BP: Biological process  
RS: Risk score  
K-M: Kaplan–Meier  
Tfh: T follicular helper.

Data Availability

The datasets used in this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Authors’ Contributions

Meng-Yang Shi and Yan-fei Mu contributed equally to this manuscript.

References

[1] P. C. Lott and L. G. Carvajal-Carmona, “Resolving gastric cancer aetiology: an update in genetic predisposition,” The Lancet Gastroenterology & Hepatology, vol. 3, no. 12, pp. 874–883, 2018.
[2] K. Gao and J. Wu, “National trend of gastric cancer mortality in China (2003–2015): a population-based study,” Cancer Communications, vol. 39, no. 1, p. 24, 2019.
[3] J. Machlowska, J. Baj, M. Sitarz, R. Maciejewski, and R. Sitarz, “Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies,” International Journal of Molecular Sciences, vol. 21, no. 11, Article ID 4012, 2020.
[4] J. Matsuoka, H. Tsugawa, and H. Suzuki, “Precision medicine approaches to prevent gastric cancer,” Gut and liver, vol. 15, no. 1, pp. 3–12, 2021.
[5] F. Kopp and J. T. Mendell, “Functional classification and experimental dissection of long noncoding RNAs,” Cell, vol. 172, no. 3, pp. 393–407, 2018.
[6] Y. T. Tan, J. F. Lin, T. Li, J. J. Li, R. H. Xu, and H. Q. Ju, “LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer,” Cancer Communications, vol. 41, no. 2, pp. 109–120, 2021.
[7] F. A. Karreth and P. P. Pandolfi, “ceRNA cross-talk in cancer: when ce-bling rivalries go awry,” Cancer Discovery, vol. 3, no. 10, pp. 1113–1121, 2013.
[8] R. L. Kan, J. Chen, and T. Sallam, “Crosstalk between epitranscriptomic and epigenetic mechanisms in gene regulation,” Trends in Genetics, vol. 38, no. 2, pp. 182–193, 2022.
[9] C. L. Smillie, T. Sirey, and C. P. Ponting, “Complexities of post-transcriptional regulation and the modeling of ceRNA crosstalk,” Critical Reviews in Biochemistry and Molecular Biology, vol. 53, no. 3, pp. 231–245, 2018.
[10] Y. An, K. L. Furber, and S. Ji, “Pseudogenes regulate parental gene expression via ceRNA network,” Journal of Cellular and Molecular Medicine, vol. 21, no. 1, pp. 185–192, 2017.
[11] L. Salmena, L. Poliseno, Y. Tay, L. Kats, and P. P. Pandolfi, “A ceRNA hypothesis: the Rosetta stone of a hidden RNA language?” Cell, vol. 146, no. 3, pp. 353–358, 2011.
[12] T. Su, T. Wang, N. Zhang et al., “Long non-coding RNAs in gastrointestinal cancers: implications for protein phosphorylation,” Biochemical Pharmacology, vol. 197, Article ID 114907, 2022.
[13] X. Tang, H. Ren, M. Guo, J. Qian, Y. Yang, and C. Gu, “Review on circular RNAs and new insights into their roles in cancer,” Computational and Structural Biotechnology Journal, vol. 19, pp. 910–928, 2021.
[14] X. Z. Zhang, H. Liu, and S. R. Chen, “Mechanisms of long non-coding RNAs in cancers and their dynamic regulations,” Cancers, vol. 12, no. 5, Article ID 1245, 2020.
[15] W. Wu, T. Yu, Y. Wu, W. Tian, J. Zhang, and Y. Wang, “The miR155HG/miR-185/ANXA2 loop contributes to glioblastoma growth and progression,” Journal of Experimental & Clinical Cancer Research, vol. 38, no. 1, p. 133, 2019.
[16] S. Zhang, S. Li, J. L. Guo, N. Li, C. N. Zhang, and J. Liu, “Integrated analysis of IncRNA-associated ceRNA network identifies two IncRNA signatures as a prognostic biomarker in gastric cancer,” Disease Markers, vol. 2021, Article ID 8886897, 16 pages, 2021.
[17] M. I. Love, W. Huber, and S. Anders, “Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2,” Genome Biology, vol. 15, no. 12, p. 550, 2014.
[18] P. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a software environment for integrated models of biomolecular interaction networks,” Genome Research, vol. 13, no. 11, pp. 2498–2504, 2003.
[19] T. Matsuoka and M. Yashiro, “Biomarkers of gastric cancer: current topics and future perspective,” World Journal of Gastroenterology, vol. 24, no. 26, pp. 2818–2832, 2018.
[20] N.-Y. Chia and P. Tan, “Molecular classification of gastric cancer,” Annals of Oncology, vol. 27, no. 5, pp. 763–769, 2016.
[21] D. Wu, P. Zhang, J. Ma et al., “Serum biomarker panels for the diagnosis of gastric cancer,” Cancer Medicine, vol. 8, no. 4, pp. 1576–1583, 2019.
[22] S.-H. Jeong, R. B. Kim, S. Y. Park et al., “Nomogram for predicting gastric cancer recurrence using biomarker gene expression,” European Journal of Surgical Oncology, vol. 46, no. 1, pp. 195–201, 2020.
[23] X. Yin, P. Wang, T. Yang et al., “Identification of key modules and genes associated with breast cancer prognosis using WGCNA and ceRNA network analysis,” Aging, vol. 13, no. 2, pp. 2519–2538, 2020.
[24] K. Zhang, L. Zhang, Y. Mi et al., “A ceRNA network and a potential regulatory axis in gastric cancer with different degrees of immune cell infiltration,” Cancer Science, vol. 111, no. 11, pp. 4041–4050, 2020.
[25] L. Xin, L. Liu, C. Liu et al., “DNA-methylation-mediated silencing of miR-7-5p promotes gastric cancer stem cell invasion via increasing Smo and Hes1,” Journal of Cellular Physiology, vol. 235, no. 3, pp. 2643–2654, 2020.
[26] J. Ma, Y. Ma, S. Chen et al., “SPARC enhances 5-FU chemosensitivity in gastric cancer by modulating epithelial-mesenchymal transition and apoptosis,” Biochemical and Biophysical Research Communications, vol. 558, pp. 134–140, 2021.
[27] X.-w. Zhang, P. Bu, L. Liu, X.-z. Zhang, and J. Li, “Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance,” Biochemical and Biophysical Research Communications, vol. 462, no. 3, pp. 227–232, 2015.

[28] T. F. Gajewski, H. Schreiber, and Y.-X. Fu, “Innate and adaptive immune cells in the tumor microenvironment,” Nature Immunology, vol. 14, no. 10, pp. 1014–1022, 2013.

[29] S.-s. Wang, W. Liu, D. Ly, H. Xu, L. Qu, and L. Zhang, “Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer,” Cellular and Molecular Immunology, vol. 16, no. 1, pp. 6–18, 2019.

[30] C. Ji, L.-S. Sun, F. Xing et al., “HTRA3 is a prognostic biomarker and associated with immune infiltrates in gastric cancer,” Frontiers in Oncology, vol. 10, Article ID 603480, 2020.

[31] Y. Jiang, X. Zheng, D. Jiao et al., “Peptidase inhibitor 15 as a novel blood diagnostic marker for cholangiocarcinoma,” EBioMedicine, vol. 40, pp. 422–431, 2019.

[32] S. Zhao, M. S. Geybels, A. Leonardson et al., “Epigenome-wide tumor DNA methylation profiling identifies novel prognostic biomarkers of metastatic-lethal progression in men diagnosed with clinically localized prostate cancer,” Clinical Cancer Research, vol. 23, no. 1, pp. 311–319, 2017.

[33] S. Tuupanen, U. A. Hänninen, J. Kondelin et al., “Identification of 33 candidate oncogenes by screening for base-specific mutations,” British journal of cancer, vol. 111, no. 8, pp. 1657–1662, 2014.